Medirom director reports 28,500-share ownership

Medirom Healthcare Technologies Inc. director Ogawa Tomoya filed an initial ownership report showing he directly holds 28,500 Common Shares of the company.

Accepted by SEC EDGAR 03/18/2026 - 01:26 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Medirom Healthcare Technologies Inc. director Ogawa Tomoya filed an initial ownership report showing he directly holds 28,500 Common Shares of the company. This filing is a baseline disclosure of his equity stake and does not reflect any new share purchases or sales.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Ogawa Tomoya

Role Director

Type	Security	Shares	Price	Value
Holding	Common Shares	--	--	--

Holdings: Common Shares — 28,500 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Ogawa Tomoya’s Form 3 filing for MRM report?

The Form 3 reports that director Ogawa Tomoya directly owns 28,500 Common Shares of Medirom Healthcare Technologies Inc. This is an initial beneficial ownership statement, establishing his starting equity position as a company insider.

Did Ogawa Tomoya buy or sell Medirom (MRM) shares in this Form 3?

No, this Form 3 does not show any share purchases or sales. It simply states that Ogawa Tomoya directly holds 28,500 Common Shares, providing a baseline of his ownership as a newly reported insider.

How many Medirom (MRM) shares does Ogawa Tomoya directly own?

Ogawa Tomoya is reported to directly own 28,500 Common Shares of Medirom Healthcare Technologies Inc. This figure reflects his total direct holdings following the reported position in the Form 3 filing, with no derivative positions listed.

What is the significance of this Form 3 for Medirom (MRM) investors?

This Form 3 establishes that director Ogawa Tomoya directly holds 28,500 Common Shares. It is a standard regulatory disclosure of insider ownership, giving investors visibility into his equity stake but not indicating any recent trading activity.

Does the Form 3 for Ogawa Tomoya disclose any derivatives in MRM?

No, the filing does not list any derivative securities such as options or warrants. It only reports a direct holding of 28,500 Common Shares, so his visible position in this filing consists solely of common equity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Ogawa Tomoya

(Last) (First) (Middle)

2-3-1 DAIBA

(Street)

MINATO-KU 135-0091

(City) (State) (Zip)

JAPAN

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Medirom Healthcare Technologies Inc. [ MRM ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Shares	28,500	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	By: /s/ Tomoya Ogawa Name: Tomoya Ogawa	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)